Swiss National Bank Takes $740,000 Position in Bioventus Inc. (NYSE:BVS)

Swiss National Bank purchased a new position in Bioventus Inc. (NYSE:BVS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 70,500 shares of the company's stock, valued at approximately $740,000. Swiss National Bank owned approximately 0.09% of Bioventus as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of BVS. Virtus Fund Advisers LLC bought a new stake in Bioventus during the third quarter worth approximately $42,000. Plato Investment Management Ltd bought a new stake in shares of Bioventus in the 4th quarter worth $38,000. Quest Partners LLC acquired a new stake in shares of Bioventus in the third quarter valued at $51,000. Quarry LP bought a new position in Bioventus during the third quarter valued at about $59,000. Finally, Arizona State Retirement System acquired a new position in Bioventus during the fourth quarter worth about $109,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Trading Down 1.2 %

Shares of Bioventus stock traded down $0.12 on Wednesday, reaching $9.26. 11,911 shares of the company were exchanged, compared to its average volume of 313,473. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38. The firm has a market capitalization of $758.39 million, a price-to-earnings ratio of -15.17 and a beta of 0.86. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a fifty day moving average price of $10.03 and a 200-day moving average price of $10.96.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BVS shares. Canaccord Genuity Group restated a "buy" rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and raised their target price for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th.

Insider Buying and Selling

In other Bioventus news, SVP Anthony D'adamio sold 4,380 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert E. Claypoole sold 28,786 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $261,952.60. Following the completion of the transaction, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. This represents a 30.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,161 shares of company stock valued at $436,364. 32.90% of the stock is owned by corporate insiders.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.